<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD01690000_2</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P05106</UniProt_ID>
  <Seq_Length>788</Seq_Length>
  <Molecule_Weight>87058</Molecule_Weight>
  <KEGG_ID>hsa:3690</KEGG_ID>
  <Orthology_ID>K06493</Orthology_ID>
  <EBI_ID>EBI-702847</EBI_ID>
  <Function_Summary>Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.</Function_Summary>
  <Pfam_ID>PF08725:Integrin_b_cyt@@PF07965:Integrin_B_tail@@PF00362:Integrin_beta</Pfam_ID>
  <Allosteric_Activator_Count>2</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>GPIIIa</Alias>
      <Alias>Platelet membrane glycoprotein IIIa</Alias>
      <Alias>CD61</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with vascular endothelial growth factor receptor 2.</Detail>
      <Keyword>Vascular endothelial growth factor receptor 2 binding</Keyword>
      <Ontology_ID>GO:0043184</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the rearrangement of both intrachain and interchain disulfide bonds in proteins.</Detail>
      <Keyword>Protein disulfide isomerase activity</Keyword>
      <Ontology_ID>GO:0003756</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a cell adhesion molecule.</Detail>
      <Keyword>Cell adhesion molecule binding</Keyword>
      <Ontology_ID>GO:0050839</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the platelet-derived growth factor receptor.</Detail>
      <Keyword>Platelet-derived growth factor receptor binding</Keyword>
      <Ontology_ID>GO:0005161</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>188</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>222</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>66</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>143</Position>
      <Original>Leu</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>141</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>242</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>321</Position>
      <Original>Met</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>150</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>586</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>306</Position>
      <Original>His</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>605</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>119</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>568</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>145</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>59</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>240</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>515</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>243</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>532</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>586</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>169</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>240</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>601</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>288</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>598</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>166</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>778</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>433</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>330</Position>
      <Original>Ile</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>400</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>453</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>662</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>145</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of an integrin binding to one of its physiological ligands.</Detail>
      <Keyword>Integrin-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0007229</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of an inactive protein kinase.</Detail>
      <Keyword>Activation of protein kinase activity</Keyword>
      <Ontology_ID>GO:0032147</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of endothelial cell proliferation.</Detail>
      <Keyword>Positive regulation of endothelial cell proliferation</Keyword>
      <Ontology_ID>GO:0001938</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The movement of a leukocyte within or between different tissues and organs of the body.</Detail>
      <Keyword>Leukocyte migration</Keyword>
      <Ontology_ID>GO:0050900</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.</Detail>
      <Keyword>Negative regulation of lipid storage</Keyword>
      <Ontology_ID>GO:0010888</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.</Detail>
      <Keyword>Positive regulation of endothelial cell migration</Keyword>
      <Ontology_ID>GO:0010595</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The adhesion of one platelet to one or more other platelets via adhesion molecules.</Detail>
      <Keyword>Platelet aggregation</Keyword>
      <Ontology_ID>GO:0070527</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to a damaged tissue, following an injury.</Detail>
      <Keyword>Angiogenesis involved in wound healing</Keyword>
      <Ontology_ID>GO:0060055</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of bone tissue loss (resorption).</Detail>
      <Keyword>Regulation of bone resorption</Keyword>
      <Ontology_ID>GO:0045124</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.</Detail>
      <Keyword>Cell adhesion</Keyword>
      <Ontology_ID>GO:0007155</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The binding of a cell to the extracellular matrix via adhesion molecules.</Detail>
      <Keyword>Cell-matrix adhesion</Keyword>
      <Ontology_ID>GO:0007160</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of low-density lipoprotein particle receptors.</Detail>
      <Keyword>Negative regulation of low-density lipoprotein particle receptor biosynthetic process</Keyword>
      <Ontology_ID>GO:0045715</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The orderly movement of a smooth muscle cell from one site to another, often during the development of a multicellular organism.</Detail>
      <Keyword>Smooth muscle cell migration</Keyword>
      <Ontology_ID>GO:0014909</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipoproteins, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.</Detail>
      <Keyword>Negative regulation of lipoprotein metabolic process</Keyword>
      <Ontology_ID>GO:0050748</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Negative regulation of lipid transport</Keyword>
      <Ontology_ID>GO:0032369</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of a tube over time, from its initial formation to a mature structure. Epithelial and endothelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues including lung and trachea, kidney, the mammary gland, the vascular system and the gastrointestinal and urinary-genital tracts.</Detail>
      <Keyword>Tube development</Keyword>
      <Ontology_ID>GO:0035295</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.</Detail>
      <Keyword>Positive regulation of peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0050731</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.</Detail>
      <Keyword>Negative regulation of macrophage derived foam cell differentiation</Keyword>
      <Ontology_ID>GO:0010745</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.</Detail>
      <Keyword>Positive regulation of vascular endothelial growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0030949</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>779</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>785</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>773</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT</Protein_Seq>
    <DNA_Seq>CGCCGCGGGAGGCGGACGAGATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGTGACTGTGCTGGCGCTGGGGGCGCTGGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAGCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGCTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATCGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCTGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCAGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATCTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTGGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGGGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAAAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTGACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGGAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAAAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACTCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCATGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTGATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTAGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCCATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAAGTCGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGCCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACGGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTTACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGACTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACCTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCAGAGGAGGACTATCGCCCTTCCCAGCAGGACGAGTGCAGCCCCCGAGAGGGTCAGCCCGTCTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGCAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAGATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACCGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTGTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTATGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGTGTGGAGTGTAAGAAGTTTGACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTACTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAATTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGTGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTGGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATCTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGCGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTCACCAATATCACGTACCGGGGCACTTAATGATAAGCAGTCATCCTCAGATCATTATCAGCCTGTGCCAGGATTGCAGGAGTCCCTGCCATCATGTTTACAGAGGACAGTATTTGTGGGGAGGGATTTCGGGGCTCAGAGTGGGGTAGGTTGGGAGAATGTCAGTATGTGGAAGTGTGGGTCTGTGTGTGTGTATGTGGGGGTCTGTGTGTTTATGTGTGTGTGTTGTGTGTGGGAGTGTGTAATTTAAAATTGTGATGTGTCCTGATAAGCTGAGCTCCTTAGCCTTTGTCCCAGAATGCCTCCTGCAGGGATTCTTCCTGCTTAGCTTGAGGGTGACTATGGAGCTGAGCAGGTGTTCTTCATTACCTCAGTGAGAAGCCAGCTTTCCTCATCAGGCCATTGTCCCTGAAGAGAAGGGCAGGGCTGAGGCCTCTCATTCCAGAGGAAGGGACACCAAGCCTTGGCTCTACCCTGAGTTCATAAATTTATGGTTCTCAGGCCTGACTCTCAGCAGCTATGGTAGGAACTGCTGGCTTGGCAGCCCGGGTCATCTGTACCTCTGCCTCCTTTCCCCTCCCTCAGGCCGAAGGAGGAGTCAGGGAGAGCTGAACTATTAGAGCTGCCTGTGCCTTTTGCCATCCCCTCAACCCAGCTATGGTTCTCTCGCAAGGGAAGTCCTTGCAAGCTAATTCTTTGACCTGTTGGGAGTGAGGATGTCTGGGCCACTCAGGGGTCATTCATGGCCTGGGGGATGTACCAGCATCTCCCAGTTCATAATCACAACCCTTCAGATTTGCCTTATTGGCAGCG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Testis</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Prostate</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Osteoblast cells</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ITGB3</Gene_Name>
    <Gene_Alias>GP3A</Gene_Alias>
    <Gene_ID>3690</Gene_ID>
    <Genbank_ACCN>NM_000212</Genbank_ACCN>
    <Protein_ACCN>NP_000203</Protein_ACCN>
    <HGNC_ID>6156</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3690</Gene_URL>
    <UCSC_ID>uc002ilj.3</UCSC_ID>
    <EMBL_ID>ENSG00000259207</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P08514</Uniprot_ID>
      <Gene_Name>ITGA2B</Gene_Name>
      <EBI_ID>EBI-702693</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-702693</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P54939</Uniprot_ID>
      <Gene_Name>TLN1</Gene_Name>
      <EBI_ID>EBI-1035421</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-1035421</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P06756</Uniprot_ID>
      <Gene_Name>ITGAV</Gene_Name>
      <EBI_ID>EBI-298282</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-298282</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P05106</Uniprot_ID>
      <Gene_Name>ITGB3</Gene_Name>
      <EBI_ID>EBI-981051</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-981051</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P26039</Uniprot_ID>
      <Gene_Name>Tln1</Gene_Name>
      <EBI_ID>EBI-1039593</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-1039593</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P05106</Uniprot_ID>
      <Gene_Name>ITGB3</Gene_Name>
      <EBI_ID>EBI-702847</EBI_ID>
      <PPI_EBI_URL>EBI-702847,EBI-702847</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Bernard-Soulier Syndrome</Disease_Name>
      <Disease_Detail>Bernard-Soulier Syndrome</Disease_Detail>
      <Disease_DB>BRN019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bernard_soulier_syndrome?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombocytopenia, Neonatal Alloimmune</Disease_Name>
      <Disease_Detail>Thrombocytopenia</Disease_Detail>
      <Disease_DB>THR095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombocytopenia_neonatal_alloimmune?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Purpura</Disease_Name>
      <Disease_Detail>Purpura</Disease_Detail>
      <Disease_DB>PRP030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/purpura?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Polycythemia</Disease_Name>
      <Disease_Detail>Polycythemia</Disease_Detail>
      <Disease_DB>PLY018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/polycythemia?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ISC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_optic_neuropathy?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fetal and Neonatal Alloimmune Thrombocytopenia</Disease_Name>
      <Disease_Detail>Fetal and Neonatal Alloimmune Thrombocytopenia</Disease_Detail>
      <Disease_DB>FTL012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fetal_and_neonatal_alloimmune_thrombocytopenia?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>NNR007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_arteritic_anterior_ischemic_optic_neuropathy?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Phimosis</Disease_Name>
      <Disease_Detail>Phimosis</Disease_Detail>
      <Disease_DB>PHM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/phimosis?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>RTN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retinal_artery_occlusion?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ART110</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arteritic_anterior_ischemic_optic_neuropathy?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombasthenia</Disease_Name>
      <Disease_Detail>Thrombasthenia</Disease_Detail>
      <Disease_DB>THR035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombasthenia?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Purpura, Posttransfusion</Disease_Name>
      <Disease_Detail>Purpura</Disease_Detail>
      <Disease_DB>PRP079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/purpura_posttransfusion?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Thrombocytopenic Purpura</Disease_Name>
      <Disease_Detail>Autoimmune Thrombocytopenic Purpura</Disease_Detail>
      <Disease_DB>ATM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_thrombocytopenic_purpura?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Fever with Renal Syndrome</Disease_Name>
      <Disease_Detail>Hemorrhagic Fever</Disease_Detail>
      <Disease_DB>HMR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_fever_with_renal_syndrome?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coronary Thrombosis</Disease_Name>
      <Disease_Detail>Coronary Thrombosis</Disease_Detail>
      <Disease_DB>CRN017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_thrombosis?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>CNT028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_artery_occlusion?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Fever</Disease_Name>
      <Disease_Detail>Hemorrhagic Fever</Disease_Detail>
      <Disease_DB>HMR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_fever?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombocytopenia</Disease_Name>
      <Disease_Detail>Thrombocytopenia</Disease_Detail>
      <Disease_DB>THR014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombocytopenia?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ANT058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anterior_ischemic_optic_neuropathy?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myelitis</Disease_Name>
      <Disease_Detail>Myelitis</Disease_Detail>
      <Disease_DB>MYL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myelitis?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombasthenia of Glanzmann and Naegeli, Itgb3-Related</Disease_Name>
      <Disease_Detail>Thrombasthenia</Disease_Detail>
      <Disease_DB>THR047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombasthenia_of_glanzmann_and_naegeli_itgb3_related?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bleeding Disorder, Platelet-Type, 16, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Bleeding Disorder, Platelet-Type, 16, Autosomal Dominant</Disease_Detail>
      <Disease_DB>BLD122</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bleeding_disorder_platelet_type_16_autosomal_dominant?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glanzmann's Thrombasthenia</Disease_Name>
      <Disease_Detail>Glanzmann's Thrombasthenia</Disease_Detail>
      <Disease_DB>GLN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glanzmanns_thrombasthenia?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=ITGB3#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness?search=ITGB3#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN ALPHAVBETA3</PDB_Title>
      <PDB_ID>1JV2</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1JV2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the extracellular segment of integrin alpha Vbeta3</PubMed_Title>
      <Author>Xiong JP</Author>
      <Journal>Science. 2001 Oct 12;294(5541):339-45</Journal>
      <PubMed_ID>11546839</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Integrin alphaIIb-beta3 transmembrane complex</PDB_Title>
      <PDB_ID>2K9J</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2K9J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling</PubMed_Title>
      <Author>Lau TL</Author>
      <Journal>EMBO J. 2009 May 6;28(9):1351-61</Journal>
      <PubMed_ID>19279667</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE</PDB_Title>
      <PDB_ID>2VDK</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta4</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF AN INTEGRIN BETA3-TALIN CHIMERA</PDB_Title>
      <PDB_ID>1MK7</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1MK7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of integrin recognition by tali</PubMed_Title>
      <Author>Garcia-Alvarez B</Author>
      <Journal>Mol Cell. 2003 Jan;11(1):49-58</Journal>
      <PubMed_ID>12535520</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A novel adaptation of the integrin PSI domain revealed from its crystal structure</PDB_Title>
      <PDB_ID>1U8C</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2TYE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel adaptation of the integrin PSI domain revealed from its crystal structure</PubMed_Title>
      <Author>Xiong JP</Author>
      <Journal>J Biol Chem. 2004 Sep 24;279(39):40252-4</Journal>
      <PubMed_ID>15299032</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complete integrin alhaVbeta3 ectodomain plus an Alpha/beta transmembrane fragment</PDB_Title>
      <PDB_ID>3IJE</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3IJE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment</PubMed_Title>
      <Author>Xiong JP</Author>
      <Journal>J Cell Biol. 2009 Aug 24;186(4):589-600</Journal>
      <PubMed_ID>19704023</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN ALPHA VBETA3 BOUND TO MN2+</PDB_Title>
      <PDB_ID>1M1X</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1M1X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the extracellular segment of integrin alpha Vbeta4 in complex with an Arg-Gly-Asp ligand</PubMed_Title>
      <Author>Xiong JP</Author>
      <Journal>Science. 2002 Apr 5;296(5565):151-5</Journal>
      <PubMed_ID>11884718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of headpiece of integrin aIIBb3 in open conformation</PDB_Title>
      <PDB_ID>3FCU</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3FCU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces</PubMed_Title>
      <Author>Zhu J</Author>
      <Journal>Mol Cell. 2008 Dec 26;32(6):849-61</Journal>
      <PubMed_ID>19111664</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST L-739758</PDB_Title>
      <PDB_ID>2VC2</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VC2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-(S)-[N-(3-PYRIDYLSULFONYL)AMINO]-3-[[2- CARBONYL-5-[2-(PIPERIDIN-4-YL)ETHYL]-THIENO[2,3- B]THIOPHENEYL]AMINO]-PROPIONIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, LGGAKQRGDV</PDB_Title>
      <PDB_ID>2VDR</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE</PDB_Title>
      <PDB_ID>2VDL</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta5</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins</PDB_Title>
      <PDB_ID>1KUZ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1KUZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 4-subunits</PubMed_Title>
      <Author>Weljie AM</Author>
      <Journal>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5878-83</Journal>
      <PubMed_ID>11983888</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins</PDB_Title>
      <PDB_ID>1KUP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1KUP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 3-subunits</PubMed_Title>
      <Author>Weljie AM</Author>
      <Journal>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5878-83</Journal>
      <PubMed_ID>11983888</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of HLA-DRA, DRB3*0101 (DR52a) with bound platelet integrin peptide associated with fetal and neonatal alloimmune thrombocytopenia</PDB_Title>
      <PDB_ID>2Q6W</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2Q6W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity</PubMed_Title>
      <Author>Parry CS</Author>
      <Journal>J Mol Biol. 2007 Aug 10;371(2):435-46</Journal>
      <PubMed_ID>17583734</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE,LGGAKQAGDV</PDB_Title>
      <PDB_ID>2VDP</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta9</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF AN INTEGRIN BETA3-TALIN CHIMERA</PDB_Title>
      <PDB_ID>1MK9</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1MK9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of integrin recognition by tali</PubMed_Title>
      <Author>Garcia-Alvarez B</Author>
      <Journal>Mol Cell. 2003 Jan;11(1):49-58</Journal>
      <PubMed_ID>12535520</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQRGDV</PDB_Title>
      <PDB_ID>2VDQ</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta10</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN AVB3 IN COMPLEX WITH AN ARG-GLY-ASP LIGAND</PDB_Title>
      <PDB_ID>1L5G</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1L5G</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01690001</ASD_Ligand>
      <PubMed_Title>Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand</PubMed_Title>
      <Author>Xiong JP</Author>
      <Journal>Science. 2002 Apr 5;296(5565):151-5</Journal>
      <PubMed_ID>11884718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST EPTIFIBATIDE</PDB_Title>
      <PDB_ID>2VDN</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta7</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQAGDV</PDB_Title>
      <PDB_ID>2VDO</PDB_ID>
      <Resolution>2.51</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta8</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen</PDB_Title>
      <PDB_ID>1TYE</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1U8C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-ACETYL-D-GLUCOSAMINE</Ligand_Name>
      <PubMed_Title>Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics</PubMed_Title>
      <Author>Xiao T</Author>
      <Journal>Nature. 2004 Nov 4;432(7013):59-67</Journal>
      <PubMed_ID>15378069</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Platelet integrin ALFAIIB-BETA3 transmembrane-cytoplasmic heterocomplex</PDB_Title>
      <PDB_ID>2KNC</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2KNC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structure of integrin AlphaIIb beta3 transmembrane-cytoplasmic heterocomplex: new insight on the mechanism of integrin activation</PubMed_Title>
      <Author>Yang J</Author>
      <Journal>To be published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR Structure of the integrin B3 cytoplasmic domain in DPC micelles</PDB_Title>
      <PDB_ID>1S4X</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1S4X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Membrane-mediated structural transitions at the cytoplasmic face during integrin activation</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4094-9</Journal>
      <PubMed_ID>15024114</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Micelle-embedded integrin beta3 transmembrane segment</PDB_Title>
      <PDB_ID>2RN0</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2RN0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the integrin beta4 transmembrane segment in phospholipid bicelles and detergent micelles</PubMed_Title>
      <Author>Lau TL</Author>
      <Journal>Biochemistry. 2008 Apr 1;47(13):4008-16</Journal>
      <PubMed_ID>18321071</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Platelet integrin alfaIIb-beta3 cytoplasmic domain</PDB_Title>
      <PDB_ID>1M8O</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1M8O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural mechanism of integrin alpha(IIb)beta(3) &quot;inside-out&quot; activation as regulated by its cytoplasmic face</PubMed_Title>
      <Author>Vinogradova O</Author>
      <Journal>Cell. 2002 Sep 6;110(5):587-97</Journal>
      <PubMed_ID>12230976</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST TIROFIBAN</PDB_Title>
      <PDB_ID>2VDM</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2VDM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta6</PubMed_Title>
      <Author>Springer TA</Author>
      <Journal>J Cell Biol. 2008 Aug 25;182(4):791-800</Journal>
      <PubMed_ID>18710925</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Bicelle-embedded integrin beta3 transmembrane segment</PDB_Title>
      <PDB_ID>2RMZ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2RMZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the integrin beta3 transmembrane segment in phospholipid bicelles and detergent micelles</PubMed_Title>
      <Author>Lau TL</Author>
      <Journal>Biochemistry. 2008 Apr 1;47(13):4008-16</Journal>
      <PubMed_ID>18321071</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of complete ectodomain of integrin aIIBb3</PDB_Title>
      <PDB_ID>3FCS</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3FCS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces</PubMed_Title>
      <Author>Zhu J</Author>
      <Journal>Mol Cell. 2008 Dec 26;32(6):849-61</Journal>
      <PubMed_ID>19111664</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04640</Pathway_ID>
      <Pathway_Title>Hematopoietic cell lineage</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05414</Pathway_ID>
      <Pathway_Title>Dilated cardiomyopathy</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cardiovascular diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05222</Pathway_ID>
      <Pathway_Title>Small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05414</Pathway_ID>
      <Pathway_Title>Dilated cardiomyopathy</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cardiovascular diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04640</Pathway_ID>
      <Pathway_Title>Hematopoietic cell lineage</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04015</Pathway_ID>
      <Pathway_Title>Rap1 signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04380</Pathway_ID>
      <Pathway_Title>Osteoclast differentiation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04611</Pathway_ID>
      <Pathway_Title>Platelet activation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.jf.b.b.b.html</SCOP_URL>
    <CATH_Class>Mainly beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1l5g</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00240008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01690001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>